---
category: news
title: "COVID-19 Vaccine Makes Moderna Stock a Valuation Momentum Trade, Says JPMorgan"
excerpt: "Because at more than $53 per share, and trailing-12-month profits of negative $1.50 a share, Moderna Inc. (MRNA) doesn't have that. Is it a reasonable price-to-sales ratio? Moderna stock has a market capitalization of $19."
publishedDateTime: 2020-05-08T13:23:00Z
webUrl: "https://www.nasdaq.com/articles/covid-19-vaccine-makes-moderna-stock-a-valuation-momentum-trade-says-jpmorgan-2020-05-08"
ampWebUrl: "https://www.nasdaq.com/articles/covid-19-vaccine-makes-moderna-stock-a-valuation-momentum-trade-says-jpmorgan-2020-05-08?amp"
cdnAmpWebUrl: "https://www-nasdaq-com.cdn.ampproject.org/c/s/www.nasdaq.com/articles/covid-19-vaccine-makes-moderna-stock-a-valuation-momentum-trade-says-jpmorgan-2020-05-08?amp"
type: article
quality: 81
heat: 81
published: false

provider:
  name: Nasdaq
  domain: nasdaq.com

topics:
  - Treatment
  - Coronavirus

secured: "n/ha640HpZKnsIqcflA7aup0u7RC3DP+hNliF76RGGdeCHqNCcHBcV6w09Cm216VoJ1PYp/Aa0eDLgHEMNZqVO5UbezZ/E0OO3GhqpkL6QELdYVEHWB9k0OG507kiTl8FmiTE7C3VrCUvINJhGQLMq8TUqz1dr9AyRRAwHfNbf2lWaUggolzdSCO2ajS1UI1FgE/mN7IyVZxNvP31HBz8N0lVTYoBKjvWB3amSXi9mes1hjXCSULnw3wcEfyNyHrXSHx8OCiJ1LOP8hKqnsRu1WJWa4PG2cAm7TNz9tUsYrnnpCrjrs3KvL85uexv3gXCHyhnklppT4HuHxjXVKoR9KqnoCqitUxswKs1nAfUzORn46lKKn+a4d2oZGXoYp6vxZckSCkF7o6MOKPSakAH9Z+UJyM8GC9asdLG9aEY0kMczzfZIA/+36gjtNynFEROV1I//DlmDine6wNyRqAYiqAlA+LQEE4q4zjI7xkAJM=;zvw5z2QQSAWaOq1Rx18JEw=="
---

